HAIN shorts grind higher ahead of May earnings
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
HAIN enters its May 8 earnings report with short sellers the most committed they have been all year — and Tuesday's 14% single-day collapse underlines why.
Short interest has become the defining feature of this setup. At 16.7% of the free float, it has climbed steadily from 14.2% in mid-March — a gain of roughly 2.5 percentage points in six weeks. The move accelerated sharply in late April, with shorts adding nearly a full percentage point of float in a single session around April 23. The ORTEX short score has held above 70 all week, a level that places HAIN in the most heavily shorted cohort in its universe. Twelve days to cover — per FINRA's fortnightly reading — means unwinding would be a slow process even if sentiment reversed.
The borrow market reflects the same directional pressure, though the cost of borrowing remains relatively modest. Cost to borrow has risen 54% over the past month to 1.36%, an elevated pace but still well within the range where supply is not genuinely constrained. Availability is still adequate — the lending pool has not been meaningfully exhausted, and the 52-week peak utilisation reading of 37% confirms shorts have faced no structural squeeze. The positioning looks more like an orderly build than a panicked pile-on.
Options traders, by contrast, are almost entirely sidelined on the downside. The put/call ratio is 0.135 — barely above its 20-day average of 0.13 and well below the 52-week high of 0.43. Call volume overwhelms puts by roughly 7-to-1. That divergence is striking: short sellers are building in size while the options market shows none of the protective hedging usually associated with a stock this distressed. Either options traders see limited incremental downside from here, or the instrument is simply too illiquid to express a view efficiently.
The Street offers no comfort for bulls. Every analyst who covers HAIN carries a hold or worse. Barclays downgraded to Underweight in mid-March, cutting its target to $0.50. At today's price of $0.64, the stock is already below most published targets — a data-consistency note: several targets in the $1.00–$1.50 range now appear stale relative to where the equity actually trades. The bear case is straightforward: organic revenue is contracting at high single digits, EPS estimates have been revised down repeatedly, and a stretched balance sheet limits the company's room to invest behind its brands. The bull case rests on potential efficiency gains and a valuation that, at a price-to-book of 0.08, prices in near-total impairment of the business. EV/EBITDA at 8.2x remains the one multiple that does not scream distress — but that multiple has been compressing steadily.
The most instructive data point ahead of the May 8 print is what happened last time. At the February 9 earnings, HAIN fell 27% on the day and extended that to -28% by the end of the week. Short interest at that point was already elevated, yet the stock still moved violently through what was presumably a crowded short base — a reminder that heavily shorted, heavily sold micro-cap names can generate outsized two-way moves at results. Castleknight Management, which entered Q1 as the largest disclosed institutional holder at 8.3% of shares, has the most at stake.
The next catalyst is straightforward: May 8, after the close. The question is whether the revenue trajectory shows any deceleration in the deterioration, or whether the 11–12% fourth-quarter decline flagged in the bear case materialises as guided.
Stocks in this article
See the live data behind this article on ORTEX.
Open HAIN on ORTEX →How this article was generated
- Generated
- 30 Apr 2026, 06:00
- Data as of
- 30 Apr 2026, 05:59
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signals
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.